# Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

> **NCT06621602** · — · ACTIVE_NOT_RECRUITING · sponsor: **CND Life Sciences** · enrollment: 100 (estimated)

## Conditions studied

- REM Behavior Disorder
- Parkinson Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06621602
- **Lead sponsor:** CND Life Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621602, "Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06621602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*